SCHEMBL18547342

SCHEMBL18547342

COC(=O)C(c1ccc(Cl)cc1)(c1ccc(Cl)cc1)c1ccc2nc(C3CC3)n(C3CN(C(=O)OC(C)(C)C)C3)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 3/20 0.40
▸ USP30 Q70CQ3 1/20 0.39
▸ P2RX3 P56373 1/20 0.38
▸ RORC P51449 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TNF P01375 1/20 0.37
▸ OPRM1 P35372 3/20 0.36
▸ OGFRL1 Q5TC84 3/20 0.36
▸ OPRK1 P41145 2/20 0.36
▸ OPRD1 P41143 2/20 0.36
▸ STS P08842 1/20 0.36
▸ PSEN1 P49768 1/20 0.36
▸ PSEN2 P49810 1/20 0.36
▸ APH1B Q8WW43 1/20 0.36
▸ NCSTN Q92542 1/20 0.36
▸ APH1A Q96BI3 1/20 0.36
▸ PSENEN Q9NZ42 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ BACE1 P56817 1/20 0.36
▸ MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18547268 0.92 CNR1 (0.44) CNR1LMNAOPRM1OGFRL1OPRD1
SCHEMBL18547120 0.91 CNR1 (0.39) CNR1USP30P2RX3RORCLMNA
SCHEMBL20679656 0.85 OPRM1 (0.41) CNR1LMNAOPRM1OGFRL1OPRK1
SCHEMBL18547273 0.85 OPRM1 (0.41) CNR1LMNAOPRM1OGFRL1OPRK1
SCHEMBL18547274 0.85 OPRM1 (0.41) CNR1LMNAOPRM1OGFRL1OPRK1
SCHEMBL18547774 0.83 CNR1 (0.44) CNR1LMNAOPRM1OGFRL1OPRD1
SCHEMBL18547101 0.83 P2RX3 (0.46) CNR1P2RX3RORCLMNASTS
SCHEMBL18547476 0.82 CNR1 (0.54) CNR1USP30P2RX3TNFPSEN1
SCHEMBL18547281 0.82 ALK (0.41) LMNAOPRM1OGFRL1OPRK1OPRD1
SCHEMBL18547700 0.81 CNR1 (0.40) CNR1LMNASTSMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190031618-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-01-31 — — US disclosed
US-10118900-B2 Benzimidazole derivatives useful as CB-1 inverse agonists JANSSEN PHARMACEUTICA NV (BE) 2018-11-06 — — US disclosed
US-20170057929-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031618-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, GPR119, CNR2 CNR1 1/4885USP30 2063/4885P2RX3 69/4885
US-20170057929-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS CNR1, GPR119, CNR2 CNR1 1/4885USP30 2019/4885P2RX3 70/4885
US-10118900-B2 Benzimidazole derivatives useful as CB-1 inverse agonists CNR1, GPR119, CNR2 CNR1 1/4885USP30 2019/4885P2RX3 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback